arrow
K

Kathleen Nguyen

University of California System
H指数:14
被引数:925

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [177Lu]Lu-PSMA-617: A Single-Center Retrospective Study

将基线PSMA PET衍生参数与接受[177Lu]Lu-PSMA-617治疗患者的毒副作用、不良事件、疼痛及生活质量相关联:一项单中心回顾性研究

2026-02-010
PRE
Prognostic Value of AI-Assisted Lesion Tracking on End-of-Treatment PSMA PET in mCRPC Patients Treated with 177Lu-PSMA: A Retrospective, Single-Center Study

AI辅助病灶追踪在(177)Lu-PSMA治疗结束PSMA PET中的预后价值:一项回顾性、单中心研究

2025-11-011
PRE
Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial
2023-12-018
PRE
Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging

确定前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描的最佳候选者作为高危前列腺癌和常规影像学阴性的男性的主要分期方法

2022-02-0118
OA
A Comprehensive Assessment of 68Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients
2021-07-2926
OAAI
Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
2021-07-1622
OA
Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality?

68Ga-PSMA-11 PET的肿瘤下沉效应: 神话还是现实?

2021-05-2853
OA
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
2021-05-2037
OA